Shares of Clinigen Group PLC (LON:CLIN) have been given a consensus rating of “Buy” by the six analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is GBX 1,222.17 ($16.57).
Several brokerages recently issued reports on CLIN. N+1 Singer reissued a “buy” rating and set a GBX 1,225 ($16.61) price target on shares of Clinigen Group in a report on Wednesday. Peel Hunt reissued a “buy” rating and set a GBX 1,350 ($18.31) price target on shares of Clinigen Group in a report on Wednesday. Berenberg Bank raised shares of Clinigen Group to a “buy” rating and lifted their price target for the company from GBX 1,200 ($16.27) to GBX 1,220 ($16.54) in a report on Thursday. Numis Securities reissued an “add” rating and set a GBX 1,208 ($16.38) price target on shares of Clinigen Group in a report on Wednesday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a GBX 1,360 ($18.44) price target on shares of Clinigen Group in a report on Tuesday, November 7th.
In other Clinigen Group news, insider Chris Rigg sold 4,955 shares of the firm’s stock in a transaction dated Thursday, November 23rd. The shares were sold at an average price of GBX 1,017 ($13.79), for a total value of £50,392.35 ($68,337.88).
About Clinigen Group
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.